MedKoo product information:

TLC388

Description of TL338: TLC388 is a synthetic analogue of camptothecin with potential antineoplastic and radio-sensitizing activities. Camptothecin analogue TLC388 selectively stabilizes topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Topoisomerase I relaxes negative super-coiled DNA during replication and transcription. This agent has been chemically modified to enhance the potency and stability of camptothecin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). 

Current developer:    TLC Biopharmaceuticals Inc., South San Francisco, CA, USA

1: Huang G, Wang H, Yang LX. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res. 2010 Mar;30(3):937-44. PubMed PMID: 20393017.